Scholarlink

<p>Lipid nanoparticles-mRNA play important roles in SARS-CoV-2 infection control. Avian coronavirus infectious bronchitis virus (IBV) comprises eight genotypes with a lack of cross-protection, causing severe economic losses to the poultry industry. Using immunoinformatics methods, five consensus sequence antigens against prevalent IBV strains were designed. Four monovalent lipid nanoparticles-mRNA (GI-19, GI-13, GI-7, GVI-1) and one quadrivalent lipid nanoparticles-mRNA were constructed to develop a broad-spectrum IBV vaccine. The safety and biodistribution of the lipid nanoparticles-mRNA were evaluated in SPF chickens and confirmed that it induced a strong and durable immune response. The lipid nanoparticles-mRNA efficacy in SPF chickens was verified in infection assays with four genotypes of IBV strains, the results showed that immunization with a 10&#xa0;µg dose provided complete protection for the chickens, while immunization with a 5&#xa0;µg dose reduced disease severity, organ damage, and mortality, and inhibited viral replication and shedding. Our results indicate that these Lipid nanoparticles-mRNA are immunogenic and protective in preclinical animal models. These data can provide a basis for IBV prevention and control and the development of mRNA vaccines against other prevalent viruses.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lipid nanoparticles-mRNA based on the consensus sequences of avian coronavirus S1 and N genes protect animals against multiple viral infections

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月30日

查看全文
  • Hongtao Xiao,
  • Wanyan Wu,
  • Siyao Yu,
  • Jiayang Chen,
  • Lijin Lai,
  • Jinlian Ren,
  • Xiaotong Yan,
  • Qiuyan Lin,
  • Libin Chen,
  • Tao Ren

摘要

Lipid nanoparticles-mRNA play important roles in SARS-CoV-2 infection control. Avian coronavirus infectious bronchitis virus (IBV) comprises eight genotypes with a lack of cross-protection, causing severe economic losses to the poultry industry. Using immunoinformatics methods, five consensus sequence antigens against prevalent IBV strains were designed. Four monovalent lipid nanoparticles-mRNA (GI-19, GI-13, GI-7, GVI-1) and one quadrivalent lipid nanoparticles-mRNA were constructed to develop a broad-spectrum IBV vaccine. The safety and biodistribution of the lipid nanoparticles-mRNA were evaluated in SPF chickens and confirmed that it induced a strong and durable immune response. The lipid nanoparticles-mRNA efficacy in SPF chickens was verified in infection assays with four genotypes of IBV strains, the results showed that immunization with a 10 µg dose provided complete protection for the chickens, while immunization with a 5 µg dose reduced disease severity, organ damage, and mortality, and inhibited viral replication and shedding. Our results indicate that these Lipid nanoparticles-mRNA are immunogenic and protective in preclinical animal models. These data can provide a basis for IBV prevention and control and the development of mRNA vaccines against other prevalent viruses.

Graphical abstract